Workflow
复星医药:控股子公司药品芦沃美替尼片中国境内启动Ⅲ期临床试验
news flash·2025-07-09 08:31

Group 1 - The core point of the article is that Fosun Pharma has initiated a Phase III clinical trial for its drug Luvofematin in China, targeting pediatric low-grade glioma [1] - The drug is a selective inhibitor of MEK1/2 and has already been approved for two indications in China [1] - The total R&D investment for this drug is approximately RMB 607 million, expected to be completed by May 2025 [1] Group 2 - According to IQVIA data, the global sales for MEK1/2 selective inhibitors are projected to reach approximately USD 2.068 billion in 2024 [1]